Epithelial-mesenchymal transition phenotype is associated with clinicopathological factors that indicate aggressive biological behavior and poor clinical outcomes in invasive breast cancer

Journal of Breast Cancer

Volumn 18, Issue 3, 2015, Pages 256-263

  Bae, Young Kyung ^a   Choi, Jung Eun ^a   Kang, Su Hwan ^a   Lee, Soo Jung ^a  

^a Yeungnam University College of Medicine   (South Korea)

Author keywords

Breast neoplasms; Epithelial mesenchymal transition; Prognosis

Indexed keywords

FIBRONECTIN; UVOMORULIN;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHENOTYPE; TISSUE MICROARRAY;

EID: 85000796440     PISSN: 17386756     EISSN: 20929900     Source Type: Journal    
DOI: 10.4048/jbc.2015.18.3.256     Document Type: Article

References (28)

1. Kim Z, Min SY, Yoon CS, Lee HJ, Lee JS, Youn HJ, et al. The basic facts of Korean breast cancer in 2011: results of a nationwide survey and breast cancer registry database. J Breast Cancer 2014;17:99-106.
2. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-90.
3. Roussos ET, Keckesova Z, Haley JD, Epstein DM, Weinberg RA, Condeelis JS. AACR special conference on epithelial-mesenchymal transition and cancer progression and treatment. Cancer Res 2010;70:7360-4.
4. Foroni C, Broggini M, Generali D, Damia G. Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact. Cancer Treat Rev 2012;38:689-97.
5. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal tran­sitions. J Clin Invest 2009;119:1429-37.
6. Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvanitis DL, et al. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer 2002;38:2362-70.
7. Christensen L. The distribution of fibronectin, laminin and tetranectin in human breast cancer with special attention to the extracellular ma­trix. APMIS Suppl 1992;26:1-39.
8. Sung CO, Park CK, Kim SH. Classification of epithelial-mesenchymal transition phenotypes in esophageal squamous cell carcinoma is strongly associated with patient prognosis. Mod Pathol 2011;24:1060-8.
9. Kim A, Bae YK, Gu MJ, Kim JY, Jang KY, Bae HI, et al. Epithelial-mes­enchymal transition phenotype is associated with patient survival in small intestinal adenocarcinoma. Pathology 2013;45:567-73.
10. Ryu HS, Park do J, Kim HH, Kim WH, Lee HS. Combination of epi­thelial-mesenchymal transition and cancer stem cell-like phenotypes has independent prognostic value in gastric cancer. Hum Pathol 2012; 43:520-8.
11. Kim A, Shin HC, Bae YK, Kim MK, Kang SH, Lee SJ, et al. Multiplica­tion of chromosome 17 centromere is associated with prognosis in pa­tients with invasive breast cancers exhibiting normal HER2 and TO­P2A status. J Breast Cancer 2012;15:24-33.
12. Bae YK, Kim A, Kim MK, Choi JE, Kang SH, Lee SJ. Fibronectin ex­pression in carcinoma cells correlates with tumor aggressiveness and poor clinical outcome in patients with invasive breast cancer. Hum Pathol 2013;44:2028-37.
13. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
14. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pa­thologists guideline recommendations for immunohistochemical test­ing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 2010;134:e48-72.
15. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncol­ogy/College of American Pathologists clinical practice guideline up­date. J Clin Oncol 2013;31:3997-4013.
16. Choi JE, Kang SH, Lee SJ, Bae YK. Androgen receptor expression pre­dicts decreased survival in early stage triple-negative breast cancer. Ann Surg Oncol 2015;22:82-9.
17. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005;17:548-58.
18. Morel AP, Lièvre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Gen­eration of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008;3:e2888.
19. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15.
20. Sarrió D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 2008;68:989-97.
21. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010;12:R68.
22. Chuthapisith S, Eremin J, El-Sheemey M, Eremin O. Breast cancer che­moresistance: emerging importance of cancer stem cells. Surg Oncol 2010;19:27-32.
23. Işeri OD, Kars MD, Arpaci F, Atalay C, Pak I, Gündüz U. Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern. Biomed Pharmacother 2011;65:40-5.
24. Creighton CJ, Chang JC, Rosen JM. Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia 2010;15:253-60.
25. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, et al. Residual breast cancers after conventional therapy display mesen­chymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 2009;106:13820-5.
26. Logullo AF, Nonogaki S, Pasini FS, Osório CA, Soares FA, Brentani MM. Concomitant expression of epithelial-mesenchymal transition biomarkers in breast ductal carcinoma: association with progression. Oncol Rep 2010;23:313-20.
27. Choi Y, Lee HJ, Jang MH, Gwak JM, Lee KS, Kim EJ, et al. Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer. Hum Pathol 2013;44:2581-9.
28. Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S, et al. Epithelial-mesenchymal transition in cancer development and its clini­cal significance. Cancer Sci 2010;101:293-9.